Traders, cannabis stakeholders, license holders, physicians, patients, regulatory authorities, entrepreneurs, capital investors, public officials, and enthusiasts, are invited to attend the CannaCon West Albuquerque at the Albuquerque Convention Center on May 17-18, 2024. The event focuses on bringing together all participants in the cannabis industry for two days of intense exploration, interaction, learning, and collaboration.
As Albuquerque is witnessing an evolving cannabis industry, this event provides a phenomenal platform for cannabis veterans and newcomers to build a solid new industry. The CannaCon West Albuquerque is engaged in boosting the West’s cannabis industry. The Albuquerque network consists of like-minded cannabis businesses that stay connected and support each other, paving the way for growth and higher returns.
Influential industry leaders and decision-makers will talk about the latest issues and regulations, trends, innovations, and strategies. They will also answer queries from attendees during discussions and interactive sessions. The CannaCon expo offers a global networking frontier where eminent canna traders and investors visit to discover new and fresh talent and ideas. This event opens up avenues for trade and opportunities for all segments of cannabis industries in the region.
CannaCon is a one-stop shop offering a gamut of services to attendees ranging from retail displays, cultivation supplies, showcasing industry innovations, world-class genetics, business and legal advice, science and technology, finance, marketing, and so on. New and seasoned entrepreneurs and industry leaders will showcase their offerings to ensure visibility among industry experts and professionals.
Attendees can meet and connect with decision-makers, veterans, and investors and grow their network at CannaCon in a fun and conducive environment.
Bookings for exhibitors and speaker sessions are available.
CannabisNewsWire (“CNW”) is a specialized communications platform with a focus on cannabis news and the cannabis sector. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled recognition and brand awareness. CNW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer
The Ontario Cannabis Store (OCS) has plans to soon allow cannabis farmgate stores to sell cannabis products that are exclusive to their location.
In an announcement posted on Thursday, May 9, the OCS says the rule change will occur in late spring, creating new opportunities for cannabis farmgate locations.
These new changes, says the OCS, will add value to its farmgate framework and “will help to create engaging destinations for consumers that elevate legal products above illegal alternatives.”
The OCS also plans to engage cannabis producers and retailers about the opportunities presented by this operating model and assess its impact on existing retailers.
Ontario’s farmgate rules allow licensed cannabis producers to apply to operate an Authorized Retail Store at their production facility. These Farmgate Stores are licensed and regulated by the Alcohol and Gaming Commission of Ontario (“AGCO”) like any other retail cannabis store.
One key difference, however, is that these producers can sell products directly from their farm rather than first sending them through the OCS distribution centre.
British Columbia and New Brunswick have also implemented their own farmgate programs. New Brunswick now has six such stores, while BC has only one currently.
Featured image of Station House Cannabis’ farmgate store in St. Thomas, ON.
Foraging for wild foods is a great way to supplement an ever-increasing food budget. It can be as easy as picking and adding dandelions to a salad. Nature’s bounty is endless as long as you gather sustainably and safely. Often considered weeds, these popular and easy-to-spot wild foods are as close as your backyard.
With bright yellow flower heads and lance-shaped leaves, dandelions contain vitamins A and C, iron, and fiber.
The young flower head is sweet and can be used to make wine and tea. The dandelion’s bitter-tasting leaves are great in salads, as a garnish, or mixed with pancake batter, cookie dough, or cakes. When dried and roasted, the roots make a great coffee replacement.
Dandelions are prevalent and easy edibles to find and identify. Gather them from a place with a clean water source that hasn’t been exposed to pesticides or fertilizers. Letting dandelions grow on your chemical-free lawn is a great way to ensure your pick is safe.
Wood Sorrel
Wood sorrel grows in full sun to part shade. It has three leaves formed into a heart shape and five-petalled yellow, white, or occasionally violet-colored flowers.
Wood sorrel is a plant native to North America, and Indigenous peoples have used it for millennia as a medicinal and edible plant. Its high levels of oxalic acid turn into oxalates when combined with other minerals in our bodies. Oxalic acid is also present in spinach and other leafy greens; however, be warned that too much oxalate in the body can lead to kidney stones.
Wood sorrel’s citrus flavor makes a great addition to salads, soups, or stews and is perfect for comfort foods on chilly fall or winter days.
Miner’s Lettuce
Easily spotted by its round leaves, miner’s lettuce is a self-seeding annual with small pink or white flowers. In spring, these rise above the disc-shaped leaves. Find it in shady locations; it can be grown as an ornamental ground cover and, in the wild, can be found on hillsides.
Given its name during the 19th century, this edible plant was often consumed by miners during the gold rush era instead of other vegetables that were hard to come by.
The entire plant is edible, but the best parts are the leaves, which can be added to salads and sandwiches and substituted for leafy greens in any dish. Plants growing in the shade are tastier, while those growing in sunny, dry conditions have a reddish tint and bitter taste.
Chickweed
Chickweed is easy to spot, especially for the first-time forager. A member of the carnation family, its lack of milky stem sap distinguishes it from other plants.
This plant grows close to the ground; its leaves are teardrop-shaped and covered with fine hairs. Prevalent late winter into summer, the plant enjoys cool, damp conditions and is often considered one the most annoying of lawn weeds.
The flavor of chickweed compares to corn silk, which is pleasant and mild. Great eaten raw, it can be a substitute for cultivated microgreens or sprouts in sandwiches and wraps.
Disclaimer: Always be sure that the food you gather is edible. Take a course, use a foraging app, and if in doubt, don’t gather what you don’t know.
Depression is a leading cause of disability that affects roughly 300 million individuals around the globe. Now, new research has determined that psilocybin is an effective treatment for symptoms of depression. This is in comparison to niacin, which was administered as the placebo, and microdoses.
Psilocybin is the primary active compound in more than 200 species of hallucinogenic mushrooms.
The research findings, carried out by investigators in the United Kingdom, was published in the BMJ. In a statement, the researchers explained that psilocybin had shown promise in alleviating depression symptoms following the administration of one or two doses with few side effects. They also highlighted that no current evidence showed that the psychedelic compound caused addiction.
In addition to this, the scientists noted that research published to date hadn’t looked into factors that could moderate the effects of psilocybin, including type of depression, dosage and prior use of the drugs.
For their study, the researchers examined randomized controlled trials that compared psilocybin as a treatment for depression to other drugs. They also explored studies where psychotherapy was utilized under both control and experimental conditions to distinguish the effects of psilocybin from those induced by psychotherapy.
They settled on seven trials that analyzed more than 400 individuals with depression. Once this was done, they measured changes in scores of depression using Hedges’s g score. In their report, the researchers explained that the change in these scores was considerably greater after psilocybin was administered.
Further analysis also revealed significant improvements with secondary depression as compared to primary depression. Prior use of psychedelics and older age were also linked to greater improvements in depression scores.
It should be noted that high variation levels between trials led to low evidence certainty to support psilocybin’s strong antidepressant effects. Additionally, a lack of diversity in study participants limited the generalizability of findings.
In their conclusion, the researchers explained that while their findings were encouraging for psilocybin as a potentially effective antidepressant, issues such as the lack of regulatory guidelines needed to be addressed before the drug could be used in clinical practice.
Investigators in an accompanying editorial who weren’t involved in the study noted that the research didn’t answer queries such as the effectiveness of psilocybin in real-world conditions. In their statement, the investigators observed the need for more data on possible effect modifiers and concluded that more and better evidence was required before any clinical recommendations could be made about psilocybin’s therapeutic use.
As companies such as Compass Pathways PLC (NASDAQ: CMPS) make progress in their psychedelic drug-development efforts, more reliable data will become available about the therapeutic effects of psilocybin and other hallucinogens.
About PsychedelicNewsWire
PsychedelicNewsWire (“PNW”) is a specialized communications platform with a focus on all aspects of psychedelics and the latest developments and advances in the psychedelics sector. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, PNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, PNW brings its clients unparalleled recognition and brand awareness. PNW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from PsychedelicNewsWire, text “Groovy” to 888-902-4192 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
Lexaria has entered an agreement wherein an existing accredited investor has exercised all their warrants to purchase shares
The company has received $4.7 million from this undertaking, prior to deducting estimated offering expenses
Proceeds fully fund Lexaria’s entire planned 2024 GLP-1 R&D program, leaving additional excess capital for general purposes
Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, just announced its entry into a warrant exercise agreement with an existing accredited investor to exercise in full certain existing warrants initially issued in October 2023 and February 2024. The warrants will be exercised at $0.97 and $2.185 per share, respectively, with the whole undertaking yielding approximately $4.7 million, prior to deducting estimated offering expenses (https://cnw.fm/YbeyA).
Proceeds from this offering will fund the 2024 GLP-1 research program and go into Lexaria’s working capital. Chris Bunka, the company’s CEO, noted that the funds will further extend its operational runway deep into 2025, an integral milestone given its project pipeline, specifically its focus on glucagon-like peptide 1 (“GLP-1”) studies for the 2024 calendar year.
“These additional cash proceeds of $4.7 million further extend Lexaria’s operational runway deep into 2025 and allow us to execute our 2024 plans at an aggressive pace,” noted Mr. Bunka.
This announcement closely follows Lexaria’s recent milestone of three additional patents to its portfolio. In April 2024, the company received two newly granted patents in the U.S. and one in Japan. The first two patents fell under the company’s patent family #24: Compositions and Methods for Treating Epilepsy, while the third fell under patent family #18: Compositions and Methods for Enhanced Delivery of Antiviral Agents. While the company maintains its standing on the value of its intellectual property and continues to pursue that, its focus for 2024 has been specifically focused on GLP-1 studies.
“Our R&D plans for 2024 are very tightly focused and will be concentrated mainly on GLP-1 investigations. We are not at this time planning additional 2024 research in antiviral nicotine, or PDE5 sectors. We have solid early-stage data in each of those areas that will allow us to build upon those at the right time,” noted Mr. Bunka (https://cnw.fm/w21gI).
The $4.7 million will be integral in realizing this objective for the company, even as it pushes for patent applications. With this, its management maintains that its hard work will prove itself in 2024, ultimately creating additional shareholder value.
NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX
About CannabisNewsWire
CannabisNewsWire (“CNW”) is a specialized communications platform with a focus on cannabis news and the cannabis sector. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled recognition and brand awareness. CNW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer
Village Farms Inc, the parent company of Pure Sunfarms, sold more than $50 million worth of cannabis in the first three months of 2024, with an adjusted EBITDA of nearly $5.6 million after expenses.
This represents a 49% year-over-year increase compared to the $34.5 million in sales in the first three months of 2023, which the company says was primarily due to higher sales of its large format flower, pre-rolls, and milled products (77% of net sales). All figures are in Canadian dollars.
These sales figures come from Village Farm’s 100% controlling interest in Pure Sunfarms and a 70% interest in Rose LifeScience, which Village Farms says has a “substantial presence in the Province of Quebec as a cannabis supplier, producer and commercialization expert.”
“The Canadian excise duty is our single largest cost of participating in the adult-use (branded) market in Canada.”
Village Farms quarterly report
The net income from its Canadian cannabis operations for the three months ending March 31, 2024, was $1.15 million, compared with a net loss of $144,000 for the three months ending March 31, 2023.
Village Farms’ sales of cannabis into the international market shrank by 11%, primarily due to a decrease in shipments to Australia. International sales were just 4% of net cannabis sales in this most recent quarterly report.
Village Farms holds EU GMP certification from the District Government of Dusseldorf and began shipping its Canadian cannabis cultivars to Germany in the second quarter of 2023.
“The Canadian excise duty is our single largest cost of participating in the adult-use (branded) market in Canada,” says the newest quarterly report.
For the three months ended March 31, 2024, the Company incurred excise duties of $20,523, compared to $18,602 for the same reporting period in 2023. The company attributes this to an increase in kilograms sold in the provincial (branded) channel in the first quarter of 2024 compared to the first quarter of 2023.
“The first quarter was an especially strong start to 2024,” said Michael DeGiglio, President and Chief Executive Officer of Village Farms International. “Canadian cannabis retail branded sales grew 28% year-over-year, all organically, as we led the top five LPs in market share growth, further narrowing the gap to number one, and achieving a new record in April. Our success in quality, innovation and brand building, together with the support of our provincial boards and retail partners, are driving these results as we delight our consumers.”
Village Farms also operates in the US cannabis market through its wholly owned subsidiary, Balanced Health, which develops and sells CBD-based products, including ingestible, edible, and topical applications.
Village Farms also operates several non-cannabis endeavours, including the marketing and distribution of tomatoes, peppers, and cucumbers in the US and Canada, as well as renewable energy.
According to the cannabis industry data platform HiFyre, Pure Sunfarms is the fastest-growing producer among the top five cannabis producers in Canada.
Recent Comments